tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Alak AM et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. 1997 J Pharm Biomed Anal pmid:9447546
Sawabe T et al. Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. 1997 Transplantation pmid:9233725
Suzuki J et al. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. 1997 J. Heart Lung Transplant. pmid:9402514
Cohen SB et al. Autocrine and paracrine regulation of human T cell IL-10 production. 1997 J. Immunol. pmid:9190906
Zucker K et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. 1997 Transpl. Immunol. pmid:9402690
Miyata Y et al. Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9405642
Taylor DO The use of tacrolimus and mycophenolate mofetil after cardiac transplantation. 1997 Curr. Opin. Cardiol. pmid:9192485
Harihara Y and Makuuchi M [Partial liver transplantation]. 1997 Nippon Naika Gakkai Zasshi pmid:9340350
Hayashi S et al. Adenovirus-mediated gene transfer to the xenogeneic liver in liver xenotransplantation: the transduction of complement regulatory factor genes (DAF and HRF20). 1997 Transplant. Proc. pmid:9193595
Wallemacq PE et al. IMx tacrolimus II vs IMx tacrolimus microparticle enzyme immunoassay evaluated in renal and hepatic transplant patients. 1997 Clin. Chem. pmid:9342026
Hohage H et al. Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. 1997 Clin Transplant pmid:9193847
Gold BG et al. A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. 1997 Exp. Neurol. pmid:9344552
Katari SR et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. 1997 Clin Transplant pmid:9193849
Ciancio G et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. 1997 Clin Transplant pmid:9193850
Koneru B et al. Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? 1997 Transplantation pmid:9197350
Cameron AM et al. FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. 1997 J. Biol. Chem. pmid:9346894
Sugitani A et al. En bloc pancreas and kidney transplantation in a patient with limited vascular access. 1997 Transplantation pmid:9197366
Hosoi R et al. Isoform-specific up-regulation by ouabain of Na+,K+-ATPase in cultured rat astrocytes. 1997 J. Neurochem. pmid:9349566
Guerini D Calcineurin: not just a simple protein phosphatase. 1997 Biochem. Biophys. Res. Commun. pmid:9199180
Krüger M et al. Inhibition of CREB- and cAMP response element-mediated gene transcription by the immunosuppressive drugs cyclosporin A and FK506 in T cells. 1997 Naunyn Schmiedebergs Arch. Pharmacol. pmid:9349628
Ohashi Y et al. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. 1997 Bone Marrow Transplant. pmid:9085743
Vu MD et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. 1997 Transplantation pmid:9422432
Oz HS and Hughes WT Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. 1997 J. Infect. Dis. pmid:9086147
Wagner K et al. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 1997 J. Heart Lung Transplant. pmid:9087870
Yasutomi M et al. Evaluation of tetrahydropyranyladriamycin as an immunosuppressant in concordant xenotransplantation. 1997 J. Heart Lung Transplant. pmid:9087871
Kitagaki K et al. Facilitation of apoptosis by cyclosporins A and H, but not FK506 in mouse bronchial eosinophils. 1997 Eur. J. Pharmacol. pmid:9430427
Morrissey PE et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. 1997 Transplantation pmid:9089224
Midtvedt K et al. Successful pregnancies in a combined pancreas and renal allograft recipient and in a renal graft recipient on tacrolimus treatment. 1997 Nephrol. Dial. Transplant. pmid:9430893
Kiuchi T et al. A hepatic graft tuberculosis transmitted from a living-related donor. 1997 Transplantation pmid:9089234
Paterson DL and Singh N Interactions between tacrolimus and antimicrobial agents. 1997 Clin. Infect. Dis. pmid:9431391
Krämer BK and Schweda F Differing proteinuria control with cyclosporin and tacrolimus. 1997 Lancet pmid:9093272
Openshaw H Peripheral neuropathy after bone marrow transplantation. 1997 Biol. Blood Marrow Transplant. pmid:9360782
Maurer M et al. Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. 1997 Am. J. Pathol. pmid:9094998
Rinaldi M et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. 1997 J. Heart Lung Transplant. pmid:9361242
Steiner JP et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. 1997 Nat. Med. pmid:9095176
Nakai A et al. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. 1997 Neurobiol. Dis. pmid:9361306
De Gasperi A and Rohrer RJ Scenario number two: sepsis and multiorgan failure after liver transplantation. 1997 Liver Transpl Surg pmid:9377761
Lang P and Baron C Molecular mechanisms of immunosuppressive chemical agents recently introduced in clinical transplantation protocols. 1997 Nephrol. Dial. Transplant. pmid:9351062
Waer M New immunosuppressive agents for organ transplantation. 1997 Acta Clin Belg pmid:9351290
Delehanty LL et al. Apoptosis in a Fas-resistant, T-cell receptor-sensitive human leukaemic T-cell clone. 1997 Immunology pmid:9155645
Sheiner PA et al. Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. 1997 Transplantation pmid:9355846
Newell KA et al. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. 1997 Transplantation pmid:9381541
Iyengar AR et al. Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. 1997 Transplantation pmid:9158008
Karlsson H and Nässberger L FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. 1997 Transplantation pmid:9355847
van Hooff JP Pneumocystis carinii pneumonia after renal transplantation. 1997 Transplantation pmid:9158038
Ishida H et al. Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats. 1997 Toxicology pmid:9355935
Siddiqui MA et al. Lymphomatoid papulosis and FK 506. 1997 Int. J. Dermatol. pmid:9159004
Wang JH and Kelly PT Attenuation of paired-pulse facilitation associated with synaptic potentiation mediated by postsynaptic mechanisms. 1997 J. Neurophysiol. pmid:9356420
Okudaira H et al. Control of allergic diseases by regulation of cytokine gene transcription. 1997 Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M pmid:9383912
Lee JW et al. Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study. 1997 Ther Drug Monit pmid:9108651
Thyagarajan GK et al. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. 1997 Ann. Thorac. Surg. pmid:9386723
Holt DW and Johnston A Tacrolimus quality assessment. 1997 Ther Drug Monit pmid:9108659
Wang MS et al. Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve. 1997 J. Pharmacol. Exp. Ther. pmid:9262378
McElwee KJ et al. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. 1997 Br. J. Dermatol. pmid:9390322
Pirsch JD et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9112351
Huang J and Schreiber SL A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391035
Nyanguile O et al. A nonnatural transcriptional coactivator. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391036
Kageyama S et al. Augmentation of natural killer cell activity induced by cytomegalovirus infection in mice treated with FK506. 1997 Acta Virol. pmid:9391652
Hossain MA et al. Immunosuppression in auxiliary partial liver transplantation with FK506 in rats. 1997 Transplant. Proc. pmid:9414861
Yu C et al. Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation. 1997 Bone Marrow Transplant. pmid:9244417
Weber M et al. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. 1997 Transplant. Proc. pmid:9414883
Floren LC et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. 1997 Clin. Pharmacol. Ther. pmid:9246018
Scantlebury VP et al. Outcome of kidney transplantation in African-Americans using tacrolimus. 1997 Transplant. Proc. pmid:9414906
Soman KV et al. Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: implications for cytokine receptor signaling. 1997 Protein Sci. pmid:9144770
Cao S et al. Potential effect of cyclosporin A in formation of cholesterol gallstones in pediatric liver transplant recipients. 1997 Dig. Dis. Sci. pmid:9246038
Gruessner RW et al. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. 1997 Transplantation pmid:9415558
Wong PW and Pessah IN Noncoplanar PCB 95 alters microsomal calcium transport by an immunophilin FKBP12-dependent mechanism. 1997 Mol. Pharmacol. pmid:9145907
McKee M et al. Steroid withdrawal in tacrolimus (FK506)-treated pediatric liver transplant recipients. 1997 J. Pediatr. Surg. pmid:9247215
Marienfeld R et al. Cyclosporin A interferes with the inducible degradation of NF-kappa B inhibitors, but not with the processing of p105/NF-kappa B1 in T cells. 1997 Eur. J. Immunol. pmid:9247567
Massicot F et al. Modulation of energy status and cytotoxicity induced by FK506 and cyclosporin A in a renal epithelial cell line. 1997 Arch. Toxicol. pmid:9248632
Newstead CG Tacrolimus in renal transplantation. 1997 Nephrol. Dial. Transplant. pmid:9249761
Neuhaus P et al. Tacrolimus-based immunosuppression after liver transplantation: a randomised study comparing dual versus triple low-dose oral regimens. 1997 Transpl. Int. pmid:9249934
Dhawan A et al. Tacrolimus (FK506) malabsorption: management with fluconazole coadministration. 1997 Transpl. Int. pmid:9249946
Michel MC et al. Comparison of old and new IMX assays for monitoring of tacrolimus levels. 1997 Transpl. Int. pmid:9287412
Brunet M [Tacrolimus (FK506): clinical, pharmacological and analytical aspects]. 1997 Med Clin (Barc) pmid:9289523
Yagi M et al. Effect of a glutamine-enriched diet on small bowel allograft during immunosuppressive therapy. 1997 Nutrition pmid:9290090
Kramer MR et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). 1997 Transplant. Proc. pmid:9290780
Holt DW and Johnston A Monitoring new immunosuppressive agents. Are the methods adequate? 1997 Drug Metabol Drug Interact pmid:9713574
Shapiro R et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. 1997 Transplant. Proc. pmid:9290809
Shaw LM Mycophenolate mofetil: pharmacokinetic strategies for optimizing immunosuppression. 1997 Drug Metabol Drug Interact pmid:9713576
Atkison P et al. Small bowel transplantation in children. 1997 Pediatr Transplant pmid:10084770
Webber SA 15 years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. 1997 Pediatr Transplant pmid:10084782
Beals CR et al. Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. 1997 Genes Dev. pmid:9106655
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Alak AM et al. A highly sensitive enzyme-linked immunosorbent assay for the determination of tacrolimus in atopic dermatitis patients. 1997 Ther Drug Monit pmid:9029754
Padhi ID et al. Interaction between tacrolimus and erythromycin. 1997 Ther Drug Monit pmid:9029762
Tsuchida Y et al. Limb allografts in rats treated with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies. 1997 J Reconstr Microsurg pmid:9044184
Wang W et al. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. 1997 Immunity pmid:9047238
Steiner JP et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9050897
Seidel ER and Ragan VL Inhibition by rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC-6 cells in culture. 1997 Br. J. Pharmacol. pmid:9051292
Wang JH and Kelly PT Postsynaptic calcineurin activity downregulates synaptic transmission by weakening intracellular Ca2+ signaling mechanisms in hippocampal CA1 neurons. 1997 J. Neurosci. pmid:9169521
Dodd DA Rapid resolution of gingival hyperplasia after switching from cyclosporine A to tacrolimus. 1997 J. Heart Lung Transplant. pmid:9171281
Savoldi E et al. [Dental and oral aspects in pediatric liver transplant patients. A comparison between the effects of cyclosporine A and FK 506]. 1997 Minerva Stomatol pmid:9173223
Rezeig MA et al. Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. 1997 Transplantation pmid:9175820
Aoki Y and Kao PN Cyclosporin A-sensitive calcium signaling represses NFkappaB activation in human bronchial epithelial cells and enhances NFkappaB activation in Jurkat T-cells. 1997 Biochem. Biophys. Res. Commun. pmid:9177287
Prasad NV et al. Metabolism of tacrolimus (FK 506) in rat liver microsomes. Effect of rifampin and dexamethasone. 1997 Res. Commun. Mol. Pathol. Pharmacol. pmid:9178371
Alak AM and Moy S Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. 1997 Transplant. Proc. pmid:9270821
Rühlmann A and Nordheim A Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation. 1997 Immunobiology pmid:9442391
Scholler G et al. Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. 1997 Transplant. Proc. pmid:9270822
Pichlmayr R et al. Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. 1997 Transplant. Proc. pmid:9270825